Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: infigratinib
Trade Name: Truseltiq
Date Designated: 09/11/2019
Orphan Designation: Treatment of cholangiocarcinoma
Orphan Designation Status: Designated/Approved/Designation Withdrawn or Revoked
Date Designation Withdrawn or Revoked: 08/04/2023
QED Therapeutics, Inc.
1800 Owens Street, 12 Floor
San Francisco, California 94148
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
1 Generic Name: infigratinib
Trade Name: Truseltiq
Marketing Approval Date: 05/28/2021
Approved Labeled Indication: Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Indication withdrawn 5/16/2024)
Exclusivity End Date: 08/04/2023 
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-